➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey
Boehringer Ingelheim
Baxter

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,758,829

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,758,829
Title:Molecular malignancy in melanocytic lesions
Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
Inventor(s): Wang; Hui (San Bruno, CA), Roberts; Christopher (Tucson, AZ), Maddula; Krishna (Tucson, AZ), Lu; Zhenquiang (Tucson, AZ), Vasicek; Tom (Minneapolis, MN), Kerns; B J (Madison, WI), Seligmann; Bruce E. (Tucson, AZ), Hoon; Dave S. B. (Los Angeles, CA)
Assignee: HTG Molecular Diagnostics, Inc. (Tucson, AZ) John Wayne Cancer Institute (Santa Monica, CA)
Application Number:14/405,739
Patent Claims:see list of patent claims

Details for Patent 9,758,829

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial HTG Molecular Diagnostics, Inc. (Tucson, AZ) John Wayne Cancer Institute (Santa Monica, CA) 2032-06-22 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
AstraZeneca
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.